London: Gilead Sciences on Thursday said its drug, Trodelvy, was being tested on bladder cancer patients who had previously been chemotherapy and others Anti-cancer treatmentCould not meet main goal of late-stage study.
Gilead shares fell 3.3 percent in extended trading after the company said the drug did not meet key goals. overall survival,
In the overall population studied, the number of deaths was higher due to the following causes: adverse events Gilead said Trodelvy, which belongs to a class of treatments called antibody-drug conjugates, is comparable to chemotherapy.
These deaths were mainly seen in the early stages of treatment and were related to the following: Neutropenic Complications — in which the level of a type of white blood cell is lower than normal — including infections.
“There is no change in the known safety profile of Trodelvy for the approved Signs of breast cancer or may be used for other investigational uses,” the company said.
The drugmaker said it is continuing to analyze the data and will discuss the results and next steps with the U.S. Food and Drug Administration.
The California-based company said continued approval for this indication may be dependent on verification of clinical benefit in confirmatory trials, including this late-stage trial.
The study tested the drug on patients undergoing chemotherapy. Metastatic Urothelial Cancer Or bladder cancer.
(Reporting by Sneha SK; Editing by Alan Barona)
gileads-trodelvy-fails-to-meet-main-goal-in-late-stage-cancer-study-et-healthworld-pharma
